Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309332 · ClinicalTrials.gov registry record · NA
AMPLATZER PFO Occluder Post Approval Study
A NA study of Stroke and Patent Foramen Ovale, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 1,214
- Enrollment target
- 20
- Study locations
NCT03309332 is a NA study of Stroke and Patent Foramen Ovale that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 1,214 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT03309332, a NA study of Stroke and Patent Foramen Ovale, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,214 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Conditions Studied
Interventions
- DEVICE AMPLATZER™ PFO Occluder
Study Locations (20)
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- USC University Hospital - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Sutter Medical Center - Sacramento
- San Diego Cardiac Center - San Diego
- University of California at San Francisco - San Francisco
- Stanford University Medical Center - Stanford
- Los Robles Hospital and Medical Center - Thousand Oaks
Arizona
- Chandler Regional Medical Center - Chandler
- St. Joseph's Hospital and Medical Center - Phoenix
- Scottsdale Healthcare Shea - Scottsdale
- Pima Heart Physicians, PC - Tucson
Colorado
- University of Colorado Hospital - Aurora
- Memorial Hospital of Colorado Springs - Colorado Springs
- Denver Heart - Denver
- South Denver Cardiology Associates PC - Littleton
Alabama
- University of Alabama at Birmingham - Birmingham
- Heart Center Research, LLC - Huntsville
Arkansas
- UAMS Medical Center - Little Rock
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,214 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2030-02-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03309332
The ClinicalTrials.gov registry entry for NCT03309332 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which AMPLATZER™ PFO Occluder is the first listed.
NCT03309332 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03309332 about?
NCT03309332 is a clinical study titled "AMPLATZER PFO Occluder Post Approval Study". The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
What is the current status of trial NCT03309332?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,214 participants. The study started on 2018-01-31. Estimated completion is 2030-02-05.
What conditions does trial NCT03309332 study?
This clinical trial studies the following conditions: Stroke, Patent Foramen Ovale.
What interventions are being tested in trial NCT03309332?
The interventions under investigation include: AMPLATZER™ PFO Occluder (DEVICE).
Who is sponsoring clinical trial NCT03309332?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03309332 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.